Furthermore, etoposide treatment of breast cancer cells increased CSC formation and elevated the level of Δ133p53β, as well as SOX2, OCT3/4, and NANOG, which can increase the risk of resistance and cancer recurrence [182]. This evidence concerns the gene SOX2 and breast carcinoma.